Context Therapeutics Faces Delisting Notice
Ticker: CNTX · Form: 8-K · Filed: Sep 2, 2025 · CIK: 1842952
| Field | Detail |
|---|---|
| Company | Context Therapeutics Inc. (CNTX) |
| Form Type | 8-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | high |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, compliance, regulatory
Related Tickers: CTX
TL;DR
CTX is getting delisted, big trouble.
AI Summary
Context Therapeutics Inc. filed an 8-K on August 28, 2025, to report a notice of delisting or failure to satisfy a continued listing rule. The company, incorporated in Delaware, is based in Philadelphia, PA.
Why It Matters
This filing indicates potential severe financial distress or non-compliance with exchange rules, which could lead to the stock being removed from trading.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's ability to remain publicly traded, posing a significant risk to investors.
Key Players & Entities
- Context Therapeutics Inc. (company) — Registrant
- August 28, 2025 (date) — Earliest event reported
- Delaware (jurisdiction) — State of incorporation
- Philadelphia, PA (location) — Principal executive offices
FAQ
What specific listing rule or standard has Context Therapeutics Inc. failed to satisfy?
The filing does not specify the exact rule or standard that Context Therapeutics Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule has been issued.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on August 28, 2025.
What is the principal executive office address for Context Therapeutics Inc.?
The principal executive office address for Context Therapeutics Inc. is 2001 Market Street, Suite 3915, Unit #15, Philadelphia, Pennsylvania 19103.
What is the company's state of incorporation?
The company's state of incorporation is Delaware.
What is the SEC file number for Context Therapeutics Inc.?
The SEC file number for Context Therapeutics Inc. is 001-40654.
Filing Stats: 546 words · 2 min read · ~2 pages · Grade level 11.3 · Accepted 2025-09-02 07:32:00
Key Financial Figures
- $0.001 — mon Stock CNTX The Nasdaq Stock Market $0.001 par value per share Indicate by check
- $1.00 — maintain a minimum closing bid price of $1.00 per share for 30 consecutive business d
Filing Documents
- cntx-20250828.htm (8-K) — 22KB
- 0001842952-25-000085.txt ( ) — 145KB
- cntx-20250828.xsd (EX-101.SCH) — 2KB
- cntx-20250828_lab.xml (EX-101.LAB) — 24KB
- cntx-20250828_pre.xml (EX-101.PRE) — 14KB
- cntx-20250828_htm.xml (XML) — 3KB
01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 28, 2025, Context Therapeutics Inc. (the "Company") received written notice (the "Extension Letter") from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until February 23, 2026 (the "Extension Deadline"), to regain compliance with Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"). The Extension Letter has no immediate effect on the Nasdaq listing or trading of the Company's common stock. As previously disclosed, on February 27, 2025, the Company received written notice from Nasdaq stating that the Company was not in compliance with the Minimum Bid Price Rule because the Company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. The Company intends to actively monitor the closing bid price of its common stock and will evaluate available options to regain compliance with the Minimum Bid Price Rule. These options include effecting a reverse stock split, if necessary. However, there can be no assurance that the Company will regain compliance with the Minimum Bid Price Rule by the Extension Deadline.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: September 2, 2025 Context Therapeutics Inc. By: /s/ Martin A. Lehr Name: Martin A. Lehr Title: Chief Executive Officer